Organon Gets 24% Sun Pharma Buyout Bid at $13.25 Floor Price

NEW YORK, May 1 —

Sun Pharma bid for Organon in all cash at a 24% premium. Organon cancelled its Q1 earnings call the same day.

What Actually Happened

Two stories collapsed into one. Organon missed Q1 revenue, saw margins fall to 3%, and pulled its earnings call. Pulling the call is the tell. Public companies don't cancel scheduled investor communications during a quiet quarter. They cancel when the lawyers tell them to. Sun Pharma's all-cash bid at a 24% premium is the reason. The European Commission also approved POHERDY, the pertuzumab biosimilar developed with Shanghai Henlius. That's a footnote when a strategic acquirer is at the door. Vanguard Capital Management disclosing a 13.7 million share position in the same window isn't a coincidence either. Arbitrage desks show up after the bid leaks.

The Catch

A 24% premium on a $13 stock works out to roughly $16 a share. The math holds if the deal closes. It doesn't if it doesn't. Sun Pharma is an Indian generics giant buying a US women's health and biosimilars portfolio. Antitrust review won't be a rubber stamp, particularly on overlapping contraceptive and biosimilar lines. The 3.6x forward multiple says the market thinks the standalone business is impaired. If regulators block the deal, the floor disappears. What's left is a 3% margin business with a missed quarter and no earnings call.

Bottom Line

Organon is no longer a fundamentals story. It's a deal-spread trade. Value investors who liked the cheap multiple have already won in cash, assuming the deal closes. Growth investors don't belong here. Watch one number: the official Sun Pharma offer price per share. Until that prints, the 24% premium is a rumor backed by a reasonable amount of evidence.

Want a full breakdown of Organon's biosimilars pipeline and the deal math? Generate a custom report at /stock/ogn.

Basis Report does not hold positions in securities discussed. This is not investment advice.